Exscientia AI Limited

2 trials 2 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

2 Recruiting

0 Completed trials

6 Countries active

6 Unique IMPs

N/A Results reported

Phase I

Phase I (FiH)

Phase I: 1 Phase I (FiH): 1

Top indications

Diffuse large B-cell lymphoma 1 Mantle cell lymphoma refractory 1 Non-small cell lung cancer 1 Squamous cell carcinoma of head and neck 1 Mantle cell lymphoma recurrent 1 Marginal zone lymphoma refractory 1 Follicular lymphoma 1 Marginal zone lymphoma recurrent 1 Richter's syndrome 1 Diffuse large B-cell lymphoma refractory 1 Marginal zone lymphoma 1 Ovarian epithelial cancer 1

Top IMPs

BEVACIZUMAB 1 CAPECITABINE 1 DOXORUBICIN HYDROCHLORIDE 1 FULVESTRANT 1 GTAEXS617 1 PACLITAXEL 1

All trials

2 total

A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting

2024-516869-36-00 Phase I 5 countries
A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan… Recruiting

2023-508227-13-00 Phase I (FiH) 1 country BEVACIZUMAB; CAPECITABINE; DOXORUBICIN HYDROCHLORIDE; FULVESTRANT; GTAEXS617; PA…

Showing 1–2 of 2 trials

← All sponsors A–Z